erythrosine has been researched along with candesartan in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benes, E; Hammond, TG; Imig, JD; Navar, LG; Orengo, S; Zhuo, JL | 1 |
| Abdeen, S; Chapman, E; Chitre, S; Hoang, QQ; Johnson, SM; Park, Y; Ray, AM; Salim, N; Sivinski, J; Stevens, M; Washburn, A | 1 |
2 other study(ies) available for erythrosine and candesartan
| Article | Year |
|---|---|
Ang II accumulation in rat renal endosomes during Ang II-induced hypertension: role of AT(1) receptor.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antibodies; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Dextrans; Endosomes; Flow Cytometry; Fluoresceins; Hypertension; Kidney; Male; Microvilli; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Renin; Systole; Tetrazoles | 2002 |
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
Topics: Biological Products; Chaperonin 10; Chaperonin 60; Escherichia coli; Humans; Inhibitory Concentration 50; Protein Folding; Rafoxanide; Salicylanilides; Suramin | 2019 |